Miraculins has registered its PreVu Non-Invasive Skin Cholesterol Point of Care (POC) test class II medical device license application with Health Canada.

The application was filed to claim that the company develops an ISO 13485 certified quality management system.

Miraculins president & CEO Christopher Moreau said receiving Health Canada clearance for the PreVu Non-Invasive Skin Cholesterol POC test will allow them to begin sell the new screening tool in Canada to help detect the hidden risk of coronary artery disease.

"We have significantly advanced discussions with distribution partners in a number of market segments and I look forward to update the market on PreVu launch plans in the near term," Moreau said.